Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 14/20 | 0.65 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.46 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3889158 | 0.82 | ERN1 (0.71) | ERN1TRIM24TRIM33TYRCDK1 | |
| SCHEMBL4751732 | 0.78 | ERN1 (0.67) | ERN1TRIM24TRIM33TYRCDK1 | |
| SCHEMBL29559365 | 0.78 | ERN1 (1.00) | ERN1TRIM24TRIM33TYR | |
| SCHEMBL120412 | 0.78 | ERN1 (1.00) | ERN1TRIM24TRIM33TYR | |
| SCHEMBL17618925 | 0.78 | ERN1 (0.67) | ERN1TRIM24TRIM33TYRCDK1 | |
| SCHEMBL29673489 | 0.77 | ERN1 (0.96) | ERN1TRIM24TRIM33TYR | |
| SCHEMBL20339337 | 0.77 | ERN1 (0.96) | ERN1TRIM24TRIM33TYR | |
| SCHEMBL1789179 | 0.77 | ERN1 (0.38) | ERN1TRIM24TRIM33TYR | |
| SCHEMBL3887594 | 0.76 | ERN1 (0.62) | ERN1TRIM24TRIM33TYRCDK1 | |
| SCHEMBL1277361 | 0.74 | APP (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| EP-2298770-A1 | Heterocyclic compounds as TrkA modulators | ChemBridge Corporation (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| EP-1960382-A1 | HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS | ChemBridge Research Laboratories, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007056155-A1 | HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS | CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | ERN1 1996/4885TRIM24 1759/4885TRIM33 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.